Amgen says Lumakras cuts risk of lung cancer progression by 34 per cent
The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
lung cancer therapy
Amgen says Lumakras plus immunotherapy for lung cancer needs further study
The findings are the first indication of how well Lumakras works in combination with drugs that help the immune system attack…
FDA approves first targetted therapy to treat aggressive form of lung cancer
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta The US Food and Drug…